Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics Inc (NASDAQ: PSTV) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapeutics for challenging cancers. This news hub provides investors and medical professionals with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access timely reports on PSTV's innovative CNS cancer therapies including rhenium (186Re) obisbemeda for glioblastoma and leptomeningeal metastases. Track progress across multiple development stages while staying informed about financial updates and manufacturing collaborations that support the company's pipeline.
Our curated collection features earnings announcements, trial result disclosures, FDA communications, and partnership expansions. All content is verified through primary sources to ensure accuracy for investment research and clinical practice decisions.
Bookmark this page for streamlined access to PSTV's latest scientific advancements and corporate developments. Check regularly for critical updates impacting the neuro-oncology treatment landscape and the company's position within precision radiotherapy markets.
Plus Therapeutics (Nasdaq: PSTV) announced that CNSide Diagnostics, its wholly owned subsidiary, has received state lab licenses to provide the CNSide® CSF Tumor Cell Enumeration (TCE) laboratory-developed test in California, Rhode Island and Maryland, bringing coverage to 48 of 50 U.S. states and serving over 90% of the U.S. population.
The CNSide® CSF assay supports diagnosis and treatment monitoring for leptomeningeal metastases, reports >11,000 tests at 120+ U.S. cancer institutions since 2020, and cites 92% sensitivity, 95% specificity, and influence on treatment decisions in 90% of cases. Tests are performed at a CLIA-certified facility in Houston and are available exclusively through CNSide Diagnostics.
Plus Therapeutics (Nasdaq: PSTV) announced two hires for its wholly owned subsidiary CNSide Diagnostics and the issuance of inducement equity grants on December 4, 2025. The company said it is scaling lab operations to address a stated $6 billion+ U.S. addressable market for a cerebrospinal fluid assay for metastatic CNS cancers and plans additional payor agreements beyond UnitedHealthcare and Humana.
The hires: Prem Gurnani (Senior Director, Lab Operations) and Elaine Luckey (Director, Quality & Regulatory). Each received options to buy 33,750 shares and 11,250 RSUs with multi-year vesting; option exercise price equals the Dec 4, 2025 closing stock price. A Form S-8 was filed covering the awards.
Plus Therapeutics (Nasdaq: PSTV) presented three clinical data updates at the WFNOS/SNO Annual Meeting (Nov 19-23, 2025) on REYOBIQ (rhenium-186 obisbemeda) in leptomeningeal metastases (LM) and recurrent glioblastoma (rGBM).
Key points: Cohort 1 of the ReSPECT-LM multidose trial began dosing (13.2 mCi) with no dose-limiting toxicity reported; prior single-dose data recommended a Phase 2 dose of 44.1 mCi. ReSPECT-GBM completed Phase 1 (1.0–41.5 mCi) with a 22.3 mCi Phase 2 dose and a maximum absorbed tumor dose of 739.5 Gy; Phase 2 has enrolled 24 of 34 patients. Imaging biomarker analyses showed dose–response correlations and median overall survival of 17 months for patients receiving ≥100 Gy versus 6 months for <100 Gy.
Plus Therapeutics (Nasdaq: PSTV) announced acceptance of an abstract for a poster spotlight with oral presentation at the San Antonio Breast Cancer Symposium (SABCS) on Dec 12, 2025. The presentation will report Phase 1 dose-escalation results for rhenium (186Re) obisbemeda (186RNL) in patients with leptomeningeal metastases (LM).
Presenter Andrew Brenner, M.D., Ph.D., will present on Dec 12, 2025 at 7:39 AM CST in Hemisfair 3 at the Henry B. Gonzalez Convention Center. LM affects roughly 5% of metastatic cancer patients and has median survival of 2–6 months, underscoring the unmet need for new CNS-targeted therapies.
Plus Therapeutics (Nasdaq: PSTV) announced completion of a Type B meeting with the U.S. Food and Drug Administration on November 7, 2025 to discuss clinical development plans for REYOBIQ in leptomeningeal metastases (LM), including design of a planned pivotal/registrational trial. The company described the meeting as constructive and said it will receive FDA meeting minutes, provide an update and guidance on next steps early in 2026, and implement focused amendments to its LM trial to align the development timeline with FDA recommendations.
Plus Therapeutics (Nasdaq: PSTV) announced that its subsidiary CNSide Diagnostics signed a national coverage agreement with Humana effective October 29, 2025, adding coverage for approximately 16 million people and bringing total CNSide CSF TCE LDT policy coverage to 67 million in the U.S.
The CNSide® Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test supports rapid diagnosis, treatment monitoring, and guidance for leptomeningeal metastases. Performance and adoption details: >11,000 tests at >120 U.S. cancer institutions since 2020; 92% sensitivity, 95% specificity; influenced treatment decisions in 90% of cases. The test is available exclusively through CNSide Diagnostics as a U.S. testing service.
Plus Therapeutics (Nasdaq: PSTV) received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
The extension does not affect the company's current listing and gives Plus until May 11, 2026 to achieve a closing bid of at least $1.00 for a minimum of 10 consecutive business days, at which point Nasdaq would confirm compliance in writing. The company cautioned there is no assurance it will regain compliance even if other listing requirements remain met.
Plus Therapeutics (Nasdaq: PSTV) will present ReSPECT-LM clinical trial results at the 40th SITC Annual Meeting and MRF Brain Metastases Summit on November 9, 2025.
Phase 1 single-dose escalation data reported at SNO/ASCO 2025 showed clinical benefit rate >75% across three outcome measures, RNA sequencing and circulating tumor cell reductions consistent with tumor cell death, and no dose-limiting toxicities up to the recommended Phase 2 dose of 44.1 mCi. REYOBIQ has received FDA Fast Track and Orphan Drug designations and enrollment in the ReSPECT-LM Dose Optimization Trial is ongoing.
Plus Therapeutics (Nasdaq: PSTV) reported Q3 2025 results and business updates focused on diagnostics, therapeutics, and capital structure.
Key points: cash and investments $16.6M at Sept 30, 2025; received a $1.9M advance as part of a $17.6M CPRIT grant; regained Nasdaq compliance; UnitedHealthcare national coverage effective Sept 15, 2025 covering >51 million people for the CNSide CSF LDT; CLIA accreditation for Houston lab and CNSide commercially available in Texas since Aug 2025; presented positive ReSPECT-LM Phase 1 results showing feasibility, favorable safety, and an efficacy signal.
Plus Therapeutics (NASDAQ: PSTV) announced commercial progress for its wholly owned subsidiary CNSide Diagnostic on Oct 21, 2025, launching a Cerebrospinal Fluid (CSF) Tumor Cell Enumeration LDT after CLIA accreditation.
Highlights include a national policy agreement with UnitedHealthcare covering ~51 million people, expansion of a purpose-built laboratory in Houston/Texas Medical Center, expanded state license applications, and senior promotions to lead commercial and technical operations.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
